AU2003270144A8 - Modulation of the synthesis of insulin - Google Patents

Modulation of the synthesis of insulin

Info

Publication number
AU2003270144A8
AU2003270144A8 AU2003270144A AU2003270144A AU2003270144A8 AU 2003270144 A8 AU2003270144 A8 AU 2003270144A8 AU 2003270144 A AU2003270144 A AU 2003270144A AU 2003270144 A AU2003270144 A AU 2003270144A AU 2003270144 A8 AU2003270144 A8 AU 2003270144A8
Authority
AU
Australia
Prior art keywords
insulin
synthesis
epsilon
modulation
casein kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003270144A
Other versions
AU2003270144A1 (en
Inventor
Reinhard Walther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Greifswald
Original Assignee
Ernst Moritz Arndt Universitaet Greifswald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ernst Moritz Arndt Universitaet Greifswald filed Critical Ernst Moritz Arndt Universitaet Greifswald
Publication of AU2003270144A1 publication Critical patent/AU2003270144A1/en
Publication of AU2003270144A8 publication Critical patent/AU2003270144A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention particularly relates to the use of substances, which modulate the activity of the proteins casein kinase II (CK II) and 14-3-3 epsilon and/or of the PcG protein EED or which influence the binding of the proteins casein kinase II (CK II) and 14-3-3 epsilon, of the PcG protein EED and/or of a fragment thereof with the protein pancreatic duodenal homeobox-1 (PDX-1) that plays a decisive roll in the glucose-induced biosynthesis of insulin, for influencing the synthesis of insulin or the provision of insulin.
AU2003270144A 2002-09-03 2003-09-02 Modulation of the synthesis of insulin Abandoned AU2003270144A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10241111A DE10241111A1 (en) 2002-09-03 2002-09-03 Modulation of insulin synthesis
DE10241111.5 2002-09-03
PCT/EP2003/009757 WO2004022772A2 (en) 2002-09-03 2003-09-02 Modulation of the synthesis of insulin

Publications (2)

Publication Number Publication Date
AU2003270144A1 AU2003270144A1 (en) 2004-03-29
AU2003270144A8 true AU2003270144A8 (en) 2004-03-29

Family

ID=31502425

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003270144A Abandoned AU2003270144A1 (en) 2002-09-03 2003-09-02 Modulation of the synthesis of insulin

Country Status (5)

Country Link
EP (1) EP1546732B1 (en)
AT (1) ATE368228T1 (en)
AU (1) AU2003270144A1 (en)
DE (2) DE10241111A1 (en)
WO (1) WO2004022772A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574424A1 (en) * 2004-07-28 2006-02-02 F. Hoffmann-La Roche Ag Insulin promoter factor 1 as target/marker of beta cell failure
EP2426202A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Kinases as targets for anti-diabetic therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498139B1 (en) * 1997-09-29 2002-12-24 Daiichi Pharmaceutical Co., Ltd. Remedies for diseases caused by insulin resistance
US6448045B1 (en) * 2000-03-10 2002-09-10 The Regents Of The University Of California Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
US6455307B1 (en) * 2001-02-08 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of casein kinase 2-alpha prime expression
US6607916B2 (en) * 2001-02-08 2003-08-19 Isis Pharmaceuticals, Inc. Antisense inhibition of Casein kinase 2-alpha expression
US6440738B1 (en) * 2001-02-08 2002-08-27 Isis Pharmaceuticals, Inc. Antisense modulation of casein kinase 2-beta expression

Also Published As

Publication number Publication date
ATE368228T1 (en) 2007-08-15
AU2003270144A1 (en) 2004-03-29
EP1546732A2 (en) 2005-06-29
DE10241111A1 (en) 2004-03-11
WO2004022772A3 (en) 2004-04-29
EP1546732B1 (en) 2007-07-25
DE50307779D1 (en) 2007-09-06
WO2004022772A2 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
MX2007006830A (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same.
WO2000002917A3 (en) Compounds and methods for modulating cadherin-mediated functions
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
TWI346660B (en)
IL160319A0 (en) Compositions and method of treating diabetes
EP1941060A4 (en) Protein demethylases comprising a jmjc domain
DE60015201D1 (en) Music playing system, corresponding control method for synchronizing composing instructions and recording medium for respective control program for synchronizing composing instructions
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
BG105886A (en) CRYSTAL STRUCTURE OF cPLA 2 AND METHODS OF IDENTIFYING ITS AGONISTS AND ANTAGONISTS
TWI350373B (en) Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
AU2002210383A1 (en) The function of a haptoglobin-haemoglobin receptor and the uses thereof
WO2000051628A3 (en) Methods of modulating lipid metabolism and storage
WO2009097014A3 (en) Therapeutic kinase modulators
PT862622E (en) METHOD OF SCREENING FOR COMPOUNDS THAT INTERACT WITH PROTEIN CINASE RAC
WO2005057344A3 (en) Material conveying system including control
DE50307779D1 (en) Modulation der insulinsynthese
WO2004029583A3 (en) Methods of secretory vimentin detection and modulation
WO2002066045A3 (en) Methods for modulating an immune response by modulating the interaction between ctla4 and pp2a
AU2001274562A1 (en) Ligand to gpr8 and dna thereof
ATE224201T1 (en) USES OF ALPHA-LACTALBUMIN COMPOSITIONS
WO2006031930A3 (en) Modulation of xbp-1 activity for treatment of metabolic disorders
WO2004016737A3 (en) Novel htnfsf13b protein variants
DE60037113D1 (en) GLYCOSYLTRANSFERASE INHIBITORS
EP1551855A4 (en) Altering memory by affecting staufen function
DE60226126D1 (en) USE OF GAMMA-GT INHIBITORS FOR THE TREATMENT OF CHRONIC DEGENERATIVE DISEASES

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase